Medicure Inc. (MCUJF)

Market Cap	6.48M
Revenue (ttm)	15.23M
Net Income (ttm)	-722.11K
Shares Out	n/a
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,066
Average Volume	3,776
Open	0.5983
Previous Close	0.6600
Day's Range	0.5983 - 0.5983
52-Week Range	0.4400 - 0.9200
Beta	0.69
RSI	56.75
Earnings Date	May 23, 2025

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 38
• Stock Exchange: OTCMKTS
• Ticker Symbol: MCUJF

Financial Performance

In 2024, Medicure's revenue was 21.91 million, an increase of 0.98% compared to the previous year's 21.69 million. Losses were -1.04 million, 12.7% more than in 2023.

Financial numbers in CAD